NexGel, Inc. (NXGL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers NexGel, Inc.'s Form 10-Q for the quarterly period ended June 30, 2025. NexGel manufactures high water content hydrogels for wound care, medical diagnostics, and cosmetics. The company operates through two primary segments: the NexGel segment (contract manufacturing, custom/white label, and branded consumer products including MedaGel, Kenkoderm, and Silly George) and the CGN segment (a 50% joint venture for converting and packaging). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $2,884,000 | $1,440,000 | $5,690,000 | $2,706,000 |
| Gross Profit | $1,258,000 | $293,000 | $2,446,000 | $519,000 |
| Gross Margin | 43.6% | 20.3% | 43.0% | 19.2% |
| Net Loss (Attributable to NexGel) | $(665,000) | $(885,000) | $(1,377,000) | $(1,738,000) |
| EPS (Basic & Diluted) | $(0.09) | $(0.14) | $(0.18) | $(0.28) |
| Cash and Equivalents | $725,000 (as of June 30, 2025) | |||
| Working Capital | $1,766,000 (as of June 30, 2025) | |||
| Total Debt (Notes Payable) | $638,000 (Total principal) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 100.3% quarter-over-quarter (Q2 2025 vs. Q2 2024) and 110.3% year-to-date. This growth is driven primarily by the Consumer Branded Products line (MedaGel, Kenkoderm, Silly George), which generated $1.88M in Q2 2025 compared to $968K in Q2 2024.
- Margin Expansion: Gross margin improved significantly from 20.3% to 43.6% in Q2, attributed to higher sales volume in branded products and improved cost structures.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 49.0% in Q2 to $1.89M. This was driven by a 91.1% increase in advertising and Amazon fees ($621K vs. $325K) and a 132.1% increase in share-based compensation ($123K vs. $53K).
- Loss Reduction: Despite higher operating expenses, the Net Loss attributable to stockholders decreased by 24.9% in Q2 ($665K vs. $885K) due to the substantial revenue and gross profit growth.
- Cash Flow: Net cash used in operating activities improved to $(807K) for the six months ended June 30, 2025, compared to $(1.79M) in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of June 30, 2025, cash was $725K, and the company incurred a net loss of $1.4M for the six-month period. Continued operations depend on raising additional capital through debt or equity.
- Recent Financing (Subsequent Event): On August 5, 2025, the company closed an "August Financing" raising approximately $950,000 gross proceeds through the sale of 413,043 shares and warrants. Additionally, a $1 million non-dilutive advance was received from partner STADA Arzneimittel AG for product launches.
- Strategic Outlook: The company plans to expand into cosmetics, athletic products, and proprietary medical devices. It continues to pursue a "roll-up" strategy for consumer brands.
- Legal Proceedings: NexGel filed a declaratory judgment lawsuit against Kiss Nail Products, Inc., regarding a patent dispute over Silly George eyelash products. An adverse outcome could result in product removal from Amazon.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in journal entry review and segregation of duties (single "super user" access). Remediation is expected by December 31, 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $725K cash balance plus the recent $950K financing to cover operating losses until profitability is achieved.
- Customer Concentration: Review Note 18; one customer represented ~10% of revenue in the first half of 2025, and three customers held 61% of accounts receivable.
- Patent Litigation: Monitor the status of the lawsuit against Kiss Nail Products, as a loss could materially impact the Silly George brand revenue.
- Internal Control Remediation: Track progress on fixing the material weaknesses in financial reporting controls by the stated December 2025 deadline.
- Warrant Liability: Note the $14K warrant liability on the balance sheet and the potential dilution from 4.76M outstanding warrants with an average exercise price of $5.18.